TickerGuard
Buy Day today: Neutral (61) Mixed market breadth · no major macro event
ACIU

AC Immune Ltd

Healthcare · Biotechnology

2.30$ -1.3% vs. previous close Closing price · As of: Nov 11, 2026

Ownership

Ownership Structure

Who owns AC Immune Ltd (ACIU)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 39.4% of the shares are freely tradable; institutional investors hold 24.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 24.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 37.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 39.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 7.0%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 99Mio.

Largest Shareholders

Institutions

Institutions ACIU
Name Stake (%) Shares Change (%) Date
Bvf Inc 19.94 19,822,436 +0.0 06/30/2026
Wells Fargo & Co 1.01 1,004,041 +0.0 06/30/2026
Renaissance Technologies Corp 0.85 840,127 +34.6 06/30/2026
Millennium Management LLC 0.78 773,594 -2.4 06/30/2026
BlackRock Inc 0.52 519,274 -1.0 06/30/2026
Dimensional Fund Advisors, Inc. 0.34 340,082 -12.8 06/30/2026
Arrowstreet Capital Limited Partnership 0.23 232,953 -42.6 06/30/2026
Citadel Advisors Llc 0.21 207,606 -22.3 06/30/2026
Morgan Stanley - Brokerage Accounts 0.13 131,815 +47.7 06/30/2026

Funds

Funds ACIU
Name Stake (%) Shares Change (%) Date
iShares Biotechnology ETF 0.48 478,621 -0.2 10/29/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?